Novo Nordisk’s obesity drug Wegovy is now recommended by EU regulatory authorities for obesity-related heart conditions. Approval in the U.S.–Novo’s biggest market for obesity drugs–by the Food and Drug Administration could be next.

The European Medicines Agency backed the use of Novo Nordisk's popular drug Wegovy to help ease heart failure in people with obesity, the Danish drugmaker said on Thursday. This marks the regulator's second backing for a use of Wegovy beyond weight loss and further strengthens Novo's case that the medicine has multiple health benefits.

Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart failure symptoms, physical limitations, and exercise function in patients with obesity-related HFpEF.

Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more rapid weight loss than its popular obesity injection Wegovy.

Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure in obese patients.